Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20504349 | 0.86 | LOXL2 (0.54) | LOXL2MAPTCA1CA2CA12 | |
| SCHEMBL16684851 | 0.84 | L3MBTL1 (0.52) | LOXL2MAPTCA1CA2CA12 | |
| SCHEMBL14966780 | 0.84 | CA1 (0.52) | LOXL2MAPTCA1CA2CA12 | |
| SCHEMBL1791209 | 0.84 | L3MBTL1 (0.52) | LOXL2MAPTCA1CA2CA12 | |
| SCHEMBL19940311 | 0.82 | MAPT (0.50) | LOXL2MAPTCA1CA2CA12 | |
| SCHEMBL28444518 | 0.82 | DPP4 (0.58) | LOXL2MAPTCA1CA2CA12 | |
| SCHEMBL5177629 | 0.82 | MAPT (0.53) | LOXL2MAPTCA1CA2CA12 | |
| SCHEMBL27542641 | 0.82 | MAPT (0.50) | LOXL2MAPTCA1CA2CA12 | |
| SCHEMBL14281202 | 0.82 | LOXL2 (0.58) | LOXL2MAPTCA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL28694343 | 0.81 | DPP4 (0.57) | LOXL2MAPTCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854681-A | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-110177783-B | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2022128850-A1 | NOVEL ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-06-23 | — | — | WO | disclosed |
| EP-3954684-A1 | PROCESS FOR THE PREPARATION OF HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | Ardelyx, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3504205-B1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210061762-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20210017177-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| EP-3752250-A1 | P300/CBP HAT INHIBITORS | Constellation Pharmaceuticals, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10793568-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20180022730-A1 | SMALL-MOLECULE INHIBITORS TARGETING DISCOIDIN DOMAIN RECEPTOR 1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | disclosed |
| US-20180022730-A1 | SMALL-MOLECULE INHIBITORS TARGETING DISCOIDIN DOMAIN RECEPTOR 1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | disclosed |
| EP-3209299-A1 | SMALL-MOLECULE INHIBITORS TARGETING DISCOIDIN DOMAIN RECEPTOR 1 AND USES THEREOF | The Board of Regents of The University of Texas System (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-0874826-A1 | NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997024331-A1 | NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1997-07-10 | — | — | WO | disclosed |
| US-5010091-A | Animal growth regulators | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-23 | — | — | US | disclosed |
| US-4654371-A | ANTI-OBESITY, HYPOGLYCEMIA AGENTS | BEECHAM GROUP P.L.C. (GB) | 1987-03-31 | — | — | US | disclosed |
| EP-0029320-A2 | Secondary ethanol amines, their preparation and their use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-05-27 | — | — | EP | disclosed |
| EP-0028105-A1 | Secondary amines, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-05-06 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061762-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | LOXL2 2317/4885MAPT 887/4885CA1 4256/4885 |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | LOXL2 2154/4885MAPT 4700/4885CA1 3577/4885 |
| US-10793568-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | LOXL2 2165/4885MAPT 4713/4885CA1 3345/4885 |
| US-20180022730-A1 | SMALL-MOLECULE INHIBITORS TARGETING DISCOIDIN DOMAIN RECEPTOR 1 AND USES THEREOF | DDR1, DDR2, DDRGK1 | LOXL2 336/4885MAPT 4803/4885CA1 4870/4885 |
| US-20210017177-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | LOXL2 2154/4885MAPT 4700/4885CA1 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.